Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Epigenetic therapy in hematological cancers

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. The environmental occurrence of Pseudomonas aeruginosa

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Bacteremia and urogenital infection with Actinomyces urogenitalis following prolonged urinary retention

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Two cases of tick-borne transmitted tularemia on Southern Zealand, Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clonal hematopoiesis in elderly twins: concordance, discordance and mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The increasing depth of knowledge about cancer biology throughout the last decades, has underlined the importance of not only genetic aberrations, but also epigenetic abnormalities in cancer cells. The extensive exploration of the cancer epigenome has provided insights into key pathways involved in tumorigenesis, as well as has allowed the development of novel epigenetic therapies. In this review, we will present the important role of epigenetic alterations in hematological diseases, with special focus on epigenetically-based targeting of hematological malignancies.

Original languageEnglish
JournalAPMIS - Journal of Pathology, Microbiology and Immunology
Volume127
Issue number5
Pages (from-to)316-328
Number of pages13
ISSN0903-4641
DOIs
Publication statusPublished - 1 May 2019

    Research areas

  • DNA (Cytosine-5-)-Methyltransferase 1/antagonists & inhibitors, DNA Methylation, Epigenesis, Genetic, Hematologic Neoplasms/drug therapy, Histone Deacetylase Inhibitors/therapeutic use, Histones/metabolism, Humans, leukemia, hematology, myeloma, lymphoma, Epigenetics

ID: 57443452